References
Havla JB, Pellkofer HL, Meinl I et al (2012) Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 69:262–264
Hakiki B, Portaccio E, Giannini M et al (2012) Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases. Mult Scler. doi:10.1177/1352458512454773
Gross CM, Baumgartner A, Rauer S, Stich O (2012) Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology. [Epub ahead of print]
Kappos L, Radue EW, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401
Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415
Rovaris M, Confavreux C, Furlan R et al (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5:343–354
Miravalle A, Jensen R, Kinkel P (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68(2):186–191
Ingwersen J, Aktas O, Kuery P et al (2011) Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol. doi:10.1016/j.clim.2011.05.005
Yednock TA, Cannon C, Fritz LC et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature 356:63–66
Conflicts of interest
Dr. Ghezzi has served on scientific advisory boards for Merck Serono, Biogen Idec Teva Pharmaceutical Industries Ltd.; has received speaker honoraria from Merck Serono, Biogen Idec, Bayer Schering Pharma, and Novartis, Serono Symposia International; served as a consultant for Novartis; and receives research support from Sanofi-Aventis, Biogen Idec, and Merck Serono. Dr. Rocca has served as consultant to Bayer Schering Pharma; received speakers’ bureaus for Biogen-Dompé and receives research support from Italian Ministry of Health. Prof. Filippi serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Genmab A/S; has received funding for travel from Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves as a consultant to Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves on speakers’ bureaus for Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; and receives research support from Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd. and Fondazione Italiana Sclerosi Multipla. Prof. Comi has served on scientific advisory boards for Bayer Schering Pharma, Merck Serono, Teva Pharmaceutical Industries Ltd., Sanofi-Aventis, Novartis, and Biogen Idec; has received speaker honoraria from Teva Pharmaceutical Industries Ltd., Sanofi-Aventis, Serono Symposia International, Foundation, Biogen Idec, Merck Serono, Novartis, and Bayer Schering Pharma. Dr. Zaffaroni has served on scientific advisory boards for Teva, Medtronics, Merck Serono and Novartis, and served as a consultant for Biogen Idec. Dr. Annovazzi has served as consultant to Biogen-Dompè and Teva Pharmaceuticals and received speaker’s bureaus for Biogen-Dompè. Dr. Baroncini and Dr. Minonzio report no disclosures.
Ethical standard
This study has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghezzi, A., Rocca, M.A., Baroncini, D. et al. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J Neurol 260, 327–329 (2013). https://doi.org/10.1007/s00415-012-6744-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-012-6744-7